Every 10-Q that Shattuck Labs, Inc. (STTK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow STTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STTK filings page.
Shattuck Labs, Inc. is a clinical-stage biotechnology company developing DR3-blocking monoclonal and bispecific antibodies for inflammatory and immune‑mediated diseases. The company’s lead program, SL‑325, completed a Phase 1 trial in healthy volunteers, showing a favorable safety profile, dose‑proportional pharmacokinetics, and durable receptor occupancy exceeding 76 days at doses of 1 mg/kg or higher. Management plans to start RECEPTIVE‑CD1, a Phase 2b trial in Crohn’s disease, in the third quarter of 2026, with induction data expected in the first half of 2028. A bispecific candidate, SL‑846, targeting DR3 and IL‑23 receptors, is in non‑human primate toxicology studies, with Phase 1 data planned for 2027.
For the six months ended June 30, 2026, Shattuck reported no revenue and a net loss of $29.9 million compared with $26.2 million a year earlier, driven mainly by higher research and development spending of $22.6 million. General and administrative expenses were $9.1 million. Cash, cash equivalents and short‑term investments totaled $208.3 million, supported by recent equity and warrant financings, and management believes this balance will fund operations for at least twelve months after the financial statements’ issuance date.
Shattuck Labs reported a first-quarter 2026 net loss of $14.8 million, slightly wider than $13.7 million a year earlier, as it expanded spending on its lead inflammatory bowel disease candidate SL-325. Research and development expenses rose to $10.9 million, while general and administrative costs were stable at $4.6 million.
Cash and cash equivalents increased to $90.4 million from $54.2 million at year-end 2025, helped by $20.6 million of common stock sales through an at-the-market program and $5.4 million of warrant exercises. Management believes this cash is sufficient to fund operations for at least 12 months as it completes a Phase 1 trial of SL-325 and prepares a Phase 2 trial in Crohn’s disease.
Shattuck Labs (STTK) reported Q3 2025 results showing a smaller loss as operating expenses declined and it recognized license revenue. License and collaboration revenue was $1,000, versus $2,997 a year ago, reflecting a one-time license to Kayak Therapeutics. Research and development expense fell to $7,618 from $16,313, and general and administrative expense was $4,098 versus $4,604. Net loss narrowed to $10,056 from $16,675.
Cash and cash equivalents were $42,548 and investments were $43,584 as of September 30, 2025, for total liquid resources of about $86.1 million. Management states this is sufficient to fund projected operations for at least the next twelve months. During August 2025, the company raised $44,480 net in a private placement of common stock, pre-funded warrants, and common stock warrants tied to future clinical data disclosure milestones. Shares outstanding were 63,151,789 at quarter-end; the company disclosed 63,279,843 outstanding as of October 23, 2025.
Shattuck Labs (STTK) reported lower operating losses and trimmed R&D activity as it pivots to its DR3 antagonist program SL-325. Cash and cash equivalents were $50.5 million and total assets were $64.4 million at June 30, 2025, while accumulated deficit stood at $407.9 million. For the six months ended June 30, 2025 the company recognized a net loss of $26.2 million, an improvement from $40.1 million a year earlier, driven by a reduction in research and development expense after winding down SL-172154 activities and completing collaboration services in 2024.
Management states current cash is sufficient to fund operations for at least twelve months. The company expects to initiate enrollment in a Phase 1 trial of SL-325 in the third quarter of 2025 and complete enrollment in the full Phase 1 by the second quarter of 2026. In a subsequent event, Shattuck announced a securities purchase agreement expected to provide approximately $46 million in upfront gross proceeds upon closing following IND clearance for SL-325, with additional potential proceeds if warrants are exercised.